Nanhua Bio Medicine Co Ltd - Asset Resilience Ratio
Nanhua Bio Medicine Co Ltd (000504) has an Asset Resilience Ratio of 11.93% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Nanhua Bio Medicine Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2024)
This chart shows how Nanhua Bio Medicine Co Ltd's Asset Resilience Ratio has changed over time. See Nanhua Bio Medicine Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nanhua Bio Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000504 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥100.46 Million | 11.93% |
| Total Liquid Assets | CN¥100.46 Million | 11.93% |
Asset Resilience Insights
- Moderate Liquidity: Nanhua Bio Medicine Co Ltd has 11.93% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Nanhua Bio Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanhua Bio Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Nanhua Bio Medicine Co Ltd (1993–2024)
The table below shows the annual Asset Resilience Ratio data for Nanhua Bio Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.10% | CN¥607.89K ≈ $88.95K |
CN¥608.17 Million ≈ $88.99 Million |
-0.12pp |
| 2023-12-31 | 0.22% | CN¥1.72 Million ≈ $251.45K |
CN¥771.38 Million ≈ $112.88 Million |
-0.08pp |
| 2022-12-31 | 0.30% | CN¥1.69 Million ≈ $246.59K |
CN¥553.06 Million ≈ $80.93 Million |
+0.23pp |
| 2021-12-31 | 0.08% | CN¥501.82K ≈ $73.43K |
CN¥659.25 Million ≈ $96.47 Million |
-0.04pp |
| 2020-12-31 | 0.12% | CN¥657.31K ≈ $96.19K |
CN¥556.14 Million ≈ $81.38 Million |
-0.24pp |
| 2019-12-31 | 0.36% | CN¥961.86K ≈ $140.75K |
CN¥268.33 Million ≈ $39.27 Million |
+0.04pp |
| 2018-12-31 | 0.32% | CN¥1.09 Million ≈ $158.85K |
CN¥342.71 Million ≈ $50.15 Million |
-0.03pp |
| 2017-12-31 | 0.35% | CN¥1.41 Million ≈ $206.03K |
CN¥404.78 Million ≈ $59.23 Million |
-0.22pp |
| 2016-12-31 | 0.56% | CN¥1.70 Million ≈ $248.19K |
CN¥301.19 Million ≈ $44.07 Million |
-2.06pp |
| 2012-12-31 | 2.62% | CN¥1.99 Million ≈ $291.59K |
CN¥76.06 Million ≈ $11.13 Million |
+1.78pp |
| 2011-12-31 | 0.84% | CN¥2.33 Million ≈ $341.54K |
CN¥276.47 Million ≈ $40.46 Million |
-0.30pp |
| 2010-12-31 | 1.14% | CN¥3.28 Million ≈ $479.91K |
CN¥286.82 Million ≈ $41.97 Million |
+0.37pp |
| 2009-12-31 | 0.77% | CN¥3.18 Million ≈ $465.74K |
CN¥412.24 Million ≈ $60.32 Million |
+0.50pp |
| 2008-12-31 | 0.27% | CN¥1.47 Million ≈ $215.32K |
CN¥536.52 Million ≈ $78.51 Million |
-0.69pp |
| 2007-12-31 | 0.96% | CN¥6.54 Million ≈ $957.26K |
CN¥681.31 Million ≈ $99.70 Million |
-1.37pp |
| 2006-12-31 | 2.33% | CN¥14.86 Million ≈ $2.17 Million |
CN¥637.48 Million ≈ $93.28 Million |
+0.58pp |
| 2005-12-31 | 1.75% | CN¥11.34 Million ≈ $1.66 Million |
CN¥648.02 Million ≈ $94.83 Million |
-0.05pp |
| 2004-12-31 | 1.80% | CN¥10.87 Million ≈ $1.59 Million |
CN¥603.88 Million ≈ $88.37 Million |
+1.20pp |
| 2003-12-31 | 0.60% | CN¥3.56 Million ≈ $521.12K |
CN¥595.75 Million ≈ $87.18 Million |
+0.13pp |
| 2002-12-31 | 0.47% | CN¥2.90 Million ≈ $424.82K |
CN¥620.07 Million ≈ $90.74 Million |
+0.01pp |
| 2001-12-31 | 0.46% | CN¥2.75 Million ≈ $402.20K |
CN¥600.98 Million ≈ $87.94 Million |
-0.93pp |
| 2000-12-31 | 1.39% | CN¥8.30 Million ≈ $1.21 Million |
CN¥597.05 Million ≈ $87.37 Million |
-0.14pp |
| 1999-12-31 | 1.53% | CN¥7.32 Million ≈ $1.07 Million |
CN¥479.49 Million ≈ $70.16 Million |
-0.27pp |
| 1998-12-31 | 1.80% | CN¥11.33 Million ≈ $1.66 Million |
CN¥631.05 Million ≈ $92.34 Million |
+0.52pp |
| 1997-12-31 | 1.27% | CN¥9.46 Million ≈ $1.38 Million |
CN¥743.86 Million ≈ $108.85 Million |
+0.43pp |
| 1996-12-31 | 0.84% | CN¥6.46 Million ≈ $944.57K |
CN¥766.94 Million ≈ $112.23 Million |
-6.37pp |
| 1995-12-31 | 7.21% | CN¥62.10 Million ≈ $9.09 Million |
CN¥861.03 Million ≈ $126.00 Million |
-0.17pp |
| 1994-12-31 | 7.38% | CN¥61.36 Million ≈ $8.98 Million |
CN¥831.10 Million ≈ $121.62 Million |
-5.30pp |
| 1993-12-31 | 12.69% | CN¥99.25 Million ≈ $14.52 Million |
CN¥782.34 Million ≈ $114.48 Million |
-- |
About Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management … Read more